New data suggests that retatrutide, a novel medication, could represent a considerable advance in size management. This treatment combines the properties of a GLP-1 agonist and a GIP analog, possibly offering a more benefit than existing therapies . Clinical research have demonstrated encouraging outcomes, including considerable declines in size a